Your browser doesn't support javascript.
loading
Phase 1 study of seviteronel, a selective CYP17 lyase and androgen receptor inhibitor, in women with estrogen receptor-positive or triple-negative breast cancer.
Bardia, Aditya; Gucalp, Ayca; DaCosta, Noashir; Gabrail, Nashat; Danso, Michael; Ali, Haythem; Blackwell, Kimberly L; Carey, Lisa A; Eisner, Joel R; Baskin-Bey, Edwina S; Traina, Tiffany A.
Affiliation
  • Bardia A; Division of Hematology and Oncology, Breast Oncology, Massachusetts General Hospital, 55 Fruit Street, Boston, MA, 02114-2696, USA. Bardia.Aditya@mgh.harvard.edu.
  • Gucalp A; Breast Medicine Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • DaCosta N; North Shore Hematology Oncology Associates, East Setauket, NY, USA.
  • Gabrail N; Gabrail Cancer Center, Canton, OH, USA.
  • Danso M; Virgina Oncology Associates, Norfolk, VA, USA.
  • Ali H; Henry Ford Hospital, Detroit, MI, USA.
  • Blackwell KL; Duke University School of Medicine, Durham, NC, USA.
  • Carey LA; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA.
  • Eisner JR; Innocrin Pharmaceuticals, Inc., Durham, NC, USA.
  • Baskin-Bey ES; Innocrin Pharmaceuticals, Inc., Durham, NC, USA.
  • Traina TA; Breast Medicine Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Breast Cancer Res Treat ; 171(1): 111-120, 2018 Aug.
Article in En | MEDLINE | ID: mdl-29744674
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Steroid 17-alpha-Hydroxylase / Androgen Receptor Antagonists / Triple Negative Breast Neoplasms / Antineoplastic Agents Limits: Aged / Aged80 / Female / Humans / Middle aged Language: En Journal: Breast Cancer Res Treat Year: 2018 Type: Article Affiliation country: United States
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Steroid 17-alpha-Hydroxylase / Androgen Receptor Antagonists / Triple Negative Breast Neoplasms / Antineoplastic Agents Limits: Aged / Aged80 / Female / Humans / Middle aged Language: En Journal: Breast Cancer Res Treat Year: 2018 Type: Article Affiliation country: United States